BioMarker Strategies Names Jerry Parrott President and Chief Executive Officer

  BioMarker Strategies Names Jerry Parrott President and Chief Executive

Biotechnology and pharmaceutical industry veteran will also join the Company’s
                              Board of Directors

Business Wire

BALTIMORE -- October 1, 2013

BioMarker Strategies today announced the appointment of Jerry Parrott as
President, Chief Executive Officer and Director, effective immediately. Mr.
Parrott will report to the Company’s Board of Directors, which will continue
to be led by Chairman Jack Davis, a co-founder and former Chairman and CEO of
Dianon Systems.

Mr. Parrott served Human Genome Sciences, Inc. as Vice President, Corporate
Communications and Public Policy from 2001 until the acquisition of HGS by
GlaxoSmithKline in 2012. Since 2006, he has also served as Chairman and
President of Maryland Health Care Product Development Corporation, a nonprofit
venture capital fund committed to helping health care products companies grow
and succeed in Maryland. He formerly held senior public policy, corporate
affairs, and other positions with Bristol-Myers Squibb Company, American
Hospital Supply Corporation and Walgreen Company.

“Jerry Parrott is a well-respected biotechnology industry executive in
Maryland and a seasoned business leader with more than 30 years of experience
providing strategic direction to a wide range of healthcare companies,” said
Mr. Davis. “I have great confidence in his ability to lead BioMarker
Strategies and ensure that our novel cancer diagnostic platform reaches its
full potential to support the selection of targeted therapies for individual
cancer patients.”

“The treatment of cancer has shifted in recent years from traditional
cytotoxic agents to more molecularly targeted therapies that may hold the
promise of greater safety and efficacy,” said Mr. Parrott. “BioMarker
Strategies has developed a unique cancer diagnostic platform called SnapPath®
that uses fresh solid tumor biopsy samples to enable the creation of
pathway-based companion diagnostic assays that will better support the choice
of which cancer patients are most likely to benefit from which targeted
therapy or combination of therapies. I believe this new technology will
ultimately speed the advance of personalized medicine for the treatment of
solid tumors.”

The Company also announced that Dr. Douglas Clark, Founder, has stepped down
as CEO to resume his academic medical career as a pathologist. Dr. Clark will
remain a Director and scientific advisor to the Company.

As Principal of Policy Advocates Inc. prior to joining HGS, Mr. Parrott’s
clients included HGS, American Type Culture Collection, Bristol-Myers Squibb,
Ciba-Geigy/Novartis, Diversa, Exogen, Genentech, HealthCare Ventures,
Hoffmann-La Roche, Western Digital, Wyeth and others. During this period, he
helped take public 3-Dimensional Pharmaceuticals, subsequently acquired by
Johnson & Johnson, and InforMax, subsequently acquired by Invitrogen. He has
helped launch important therapeutic products in immunology, oncology,
infectious disease and pain relief, and has helped bring two prescription
products over the counter.

Mr. Parrott is a Director of Noxilizer Inc., MdBio, and the Tech Council of
Maryland, and Senior Advisor to the Maryland Life Sciences Advisory Board. He
formerly served as Chair of the Biotechnology Industry Organization (BIO)
Committee on Outreach and Alliance Development, Chair of the Rx Partners
health care reform coalition, Founding Director of BioHealth Innovation,
Founding Trustee of the Foundation for Genetic Medicine, and Trustee of the
Committee for Economic Development. He received his B.A. from the University
of South Florida and attended graduate school as a University Fellow at
Northwestern University.

About BioMarker Strategies

BioMarker Strategies has developed its novel SnapPath® live tumor cell
processing system to generate PathMAP™ profiles of solid tumors to promote
improved cancer drug development and better inform selection of targeted
therapies for cancer patients. PathMAP™ profiles are phosphoprotein-based,
phenotypic profiles derived from ex vivo exposure of fresh solid tumor samples
to targeted therapies in the SnapPath® device. These functional profiles
provide information about the activated signal transduction network of live
tumor cells that are not possible using static, traditional biomarkers from
dead, fixed tumor tissue. The Company recently published data from its
preclinical and clinical collaboration in advanced melanoma in PlosOne. The
Company is located at the Johns Hopkins Science + Technology Park in
Baltimore. The development of the SnapPath® system was supported with
significant funding from the National Cancer Institute. For more information
about BioMarker Strategies, please refer to

Forward Looking Statement

This press release may contain "forward-looking statements" (within the
meaning of the Private Securities Litigation Act of 1995) that inherently
involve risk and uncertainties. BioMarker Strategies generally uses words such
as "believe," "may," "could," "will," "intend," "expect," "anticipate,"
"plan," and similar expressions to identify forward-looking statements. One
should not place undue reliance on these forward-looking statements. BioMarker
Strategies’ actual results could differ materially from those anticipated in
the forward-looking statements for many unforeseen factors. Although BioMarker
Strategies believes the expectations reflected in the forward-looking
statements are reasonable, they relate only to events as of the date on which
the statements are made, and future results, levels of activity, performance
or achievements may not meet these expectations. The Company does not intend
to update any of the forward-looking statements after the date of this press
release to conform these statements to actual results or to changes in the
Company’s expectations, except as required by law.


BioMarker Strategies
Jerry Parrott, 410-522-1008
Press spacebar to pause and continue. Press esc to stop.